Have a question?
Please get in touch with our team in case of any queries
U.S. OTC DRUGS MARKET SIZE TO REACH USD 43.18 BILLION BY 2026, GROWING AT A CAGR OF 4.01% DURING THE PERIOD 2021-2026
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
U.S. OTC DRUGS MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| MARKET SIZE (REVENUE) | USD 43.18 BILLION (2026) |
| Market Size | |
| CAGR | 4.01% (2021-2026) |
| Base Year | 2020 |
| Historic Year | |
| Forecast Year | 2021 –2026 |
| Market Segments | Product Type (Cold & Cough, Analgesics, Dietary Supplements, Gastrointestinal, Dermatology, Ophthalmic, and Others), Indication (Infection, Pain, Heartburn, Immune/Health Booster, and Others), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others) |
| Geographic Analysis | United States |
| Countries Covered |
U.S. OTC DRUGS MARKET INSIGHTS
The U.S. OTC drugs market size to reach USD 43.18 billion by 2026, growing at a CAGR of 4.01% during the forecast period. With the rise in self-medication among the US population, the demand for on-the-counter (OTC) drugs are significantly increasing. COVID-19 outbreak has considerably influenced the sales of these drugs with the increased focus on personal health. The expansion in the number of OTC medicines in the region by manufacturing companies and switching prescriptions to OTC drugs highly contributes to market growth. The demand for on-the-counter drugs has constantly been increasing with the rise of private labels, online sales, and the number of OTC product launches in the upcoming years. Recently, the sales of OTC medicines have been growing through online platforms, thereby benefitting private retailers.
U.S. OTC DRUGS MARKET: KEY HIGHLIGHTS
- In 2020, online pharmacies and hospital pharmacies segments accounted for the most significant U.S. OTC drugs market shares of 20.60% and 18.50%, respectively.
- Based on indication, the infection segment is anticipated to grow with the highest incremental growth of USD 2.78 billion during the forecast period.
- Online retail giants like Amazon, which recently launched a private label line called Basic Care, contribute to the US OTC drugs market trend.
- In the past 30 years, the FDA has converted more than 700 prescription (Rx) products to OTC status.
KEY OPPORTUNITIES IN THE MARKET:
- Impact of healthcare reforms on OTC drugs
- OTC product launches & replacement of prescription drugs
- Private labels & online sales of OTC medicines
- Switching of prescription drugs to OTC drugs
MARKET SHARE & SEGMENTS
- There is a wide and powerful array of OTC, supplemental, and herbal preparations to treat patients with upper and lower GI problems accelerating the market's growth in the US.
- The demand for cold and cough OTC drugs has already been high, and the dietary supplements are expected to have a higher growth rate mainly due to COVID-19.
- The increasing population and prevalence of digestive and cardiovascular problems accompanied by a sedentary lifestyle will increase demand for on-the-counter drugs.
- The online pharmacies distribution channel segment is anticipated to witness an incremental growth of USD 2.90 billion during the forecast period.
- To reinforce the competitive position, OTC companies may consider acquiring brands rather than companies.
- The advent of COVID-19 led to an increased dependence on online pharmacies for purchasing medicines fueling the demand for OTC medicines.
IMPACT OF COVID-19
During COVID-19, healthcare practitioners played a critical part in educating patients on OTC treatments and usage. During the COVID-19 pandemic, most people were treating themselves at home with the strict regulation of lockdown, thereby surging the growth of the U.S. OTC drugs market. Consumers benefit from the availability of OTCs and their physicians endorsing OTC usage. Both groups acknowledge the downside of OTC treatment. Companies are increasing their productivity to meet the high demand during the COVID-19.
COMPETITIVE LANDSCAPE
Leading companies are constantly consolidating their market position through strategic and high-profile mergers and acquisitions. Governments across the US are likely to sponsor campaigns to enhance health education, increasing self-medication. The OTC drugs market in the US is highly competitive and fragmented with the presence of various players. Many leading companies have a broad portfolio of OTC products that the major vendors acquire to strengthen their market value and emerge as the top player in the industry. Vendors are increasingly developing new and more effective products suitable for self-medication to boom in the US OTC drugs market.
The U.S. OTC drugs market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:
- Product Type
- Cold & Cough
- Analgesics
- Dietary Supplements
- Gastrointestinal
- Dermatology
- Ophthalmic
- Others
- Indication
- Infection
- Pain
- Heartburn
- Immune/Health Booster
- Others
- Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
Frequently Asked Questions
What is the market size and forecast for the U.S. OTC drugs industry?
What are the different distribution channels for the OTC drugs?
Who are the key players in the on-the-counter drugs industry?
Which is the leading segment in the US OTC drugs market?
What is the impact of COVID-19 on the U.S. OTC drugs market?
The U.S. OTC drugs market by revenue is expected to grow at a CAGR of 4.01% during the period 2021–2026.
The following factors are likely to contribute to the growth of the U.S. OTC drugs market during the forecast period:
- Growing Trend of Self Medication & Self Care
- High Acceptance of Private Labels & Online Sales of OTC Drugs
- Growing Healthcare Savings by OTC Drugs
- Rising of Patent Expirations of Prescription Drugs
Base Year: 2020
Forecast Year: 2021–2026
The study considers the U.S. OTC drugs market's present scenario and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Key Company Profiles
- Johnson & Johnson
- Business Overview
- Product Offerings
- Key Strengths
- Key Strategies
- Key Opportunities
- GlaxoSmithKline
- Bayer AG
- Teva Pharmaceutical Industries
Other Prominent Vendors
- Abbott
- Business Overview
- Product Offerings
- Achelios
- Alcon
- American Health
- Amway
- Aytu Consumer Health
- Bausch Health Companies
- BioGaia
- Colgate-Palmolive Company
- Herbalife Nutrition
- Perrigo Company
- Prestige Consumer Health
- Procter & Gamble
- Reckitt Benckiser Group
- Sanofi-Aventis
- Sun Pharmaceutical Industries
- The Bountiful Company
- Viatris
Segmentation by Product Type
- Cold & Cough
- Analgesics
- Dietary Supplements
- Gastrointestinal
- Dermatology
- Ophthalmic
- Others
Segmentation by Indication
- Infection
- Pain
- Heartburn
- Immune/Health Booster
- Others
Segmentation by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Others
Exhibit 1 Segmentation of OTC Drugs Market in US
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 OTC Drugs Available Under Various Therapeutics Classes in US
Exhibit 4 OTC Therapeutic Category Trends
Exhibit 5 Impact of Private Labels & Online Sales of OTC Drugs
Exhibit 6 Impact of Patent Expirations of Prescription Drugs
Exhibit 7 Impact of Product Launches & Replacement of Prescription Drugs
Exhibit 8 Impact of Healthcare Reforms on OTC Drugs
Exhibit 9 Impact of Growing Trend of Self Medication & Self Care
Exhibit 10 Impact of OTC Drugs Treating Serious Health Conditions
Exhibit 11 Impact of Switching of Prescription Drugs to OTC Drugs
Exhibit 12 Impact of Growing Healthcare Savings by OTC Drugs
Exhibit 13 OTC Drug Savings Based on Product Category 2020 (% share)
Exhibit 14 Impact of Abuse of OTC Drugs
Exhibit 15 List of OTC Drugs Abused
Exhibit 16 Impact of Risk of Side Effects by OTC Drugs
Exhibit 17 Impact of Growing Alternatives to OTC Drugs
Exhibit 18 OTC Drugs Market in US by Product 2020 &2026 (% share)
Exhibit 19 OTC Drugs Market in US by Indication 2020 &2026 (% shares)
Exhibit 20 OTC Drugs Market in US by Distribution Channel 2020 &2026
Exhibit 21 OTC Drugs Market in US 2020–2026 ($ billion)
Exhibit 22 Advantages of OTC Drugs Among Physicians and Consumers
Exhibit 23 Five Forces Analysis 2020
Exhibit 24 Incremental Growth by Product Type 2020 & 2026
Exhibit 25 OTC Drugs Market in the US by Product Type
Exhibit 26 OTC Drugs to Treat Medical Conditions (%)
Exhibit 27 OTC Drugs Market in US by Cold & Cough: Incremental & Absolute Growth
Exhibit 28 OTC Drugs Market in US by Cold & Cough 2020–2026 ($ billion)
Exhibit 29 OTC Drugs Market in US by Analgesics: Incremental & Absolute Growth
Exhibit 30 OTC Drugs Market in US by Analgesics 2020–2026 ($ billion)
Exhibit 31 OTC Drugs Market in the US by Dietary Supplements: Incremental & Absolute Growth
Exhibit 32 OTC Drugs Market in US by Dietary Supplements 2020–2026 ($ billion)
Exhibit 33 OTC Drugs Market in the US by Gastrointestinal: Incremental & Absolute Growth
Exhibit 34 OTC Drugs Market in US by Gastrointestinal 2020–2026 ($ billion)
Exhibit 35 OTC Drugs Market in US by Dermatology: Incremental & Absolute Growth
Exhibit 36 OTC Drugs Market in US by Dermatology 2020–2026 ($ billion)
Exhibit 37 OTC Drugs Market in US by Ophthalmic: Incremental & Absolute Growth
Exhibit 38 OTC Drugs Market in US by Ophthalmic 2020–2026 ($ billion)
Exhibit 39 OTC Drugs Market in US: Incremental & Absolute Growth
Exhibit 40 OTC Drugs Market in US by Others 2020–2026 ($ billion)
Exhibit 41 Incremental Growth by Indication 2020 & 2026
Exhibit 42 OTC Drugs Market in the US by Indication
Exhibit 43 OTC Drugs Market in US by Indication: Incremental Growth
Exhibit 44 OTC Drugs Market in US by Indication: Absolute Growth
Exhibit 45 OTC Drugs Market in US by Infection: Incremental & Absolute Growth
Exhibit 46 OTC Drugs Market in US by Infection 2020–2026 ($ billion)
Exhibit 47 OTC Drugs Market in US by Pain: Incremental & Absolute Growth
Exhibit 48 OTC Drugs Market in the US by Pain 2020–2026 ($ billion)
Exhibit 49 OTC Drugs Market in US by Heartburn: Incremental & Absolute Growth
Exhibit 50 OTC Drugs Market in US by Heartburn 2020–2026 ($ billion)
Exhibit 51 OTC Drugs Market in US by Immune/ Health Booster: Incremental & Absolute Growth
Exhibit 52 OTC Drugs Market in US by Immune/ Health Booster 2020–2026 ($ billion)
Exhibit 53 OTC Drugs Market in US by Others: Incremental & Absolute Growth
Exhibit 54 OTC Drugs Market in US by Others 2020–2026 ($ billion)
Exhibit 55 Incremental Growth by Distribution Channel 2020 & 2026
Exhibit 56 OTC Drugs Market in the US by Distribution Channel
Exhibit 57 OTC Drugs Market in US by Distribution Channel: Incremental Growth
Exhibit 58 OTC Drugs Market in US by Distribution Channel: Absolute Growth
Exhibit 59 OTC Drugs Market in US by Retail Pharmacies: Incremental & Absolute Growth
Exhibit 60 OTC Drugs Market in the US by Retail Pharmacies 2020–2026 ($ billion)
Exhibit 61 OTC Drugs Market in US by Hospital Pharmacies: Incremental & Absolute Growth
Exhibit 62 OTC Drugs Market in US by Hospital Pharmacies 2020–2026 ($ billion)
Exhibit 63 OTC Drugs Market in the US by Online Pharmacies: Incremental & Absolute Growth
Exhibit 64 OTC Drugs Market in US by Online Pharmacies 2020–2026 ($ billion)
Exhibit 65 OTC Drugs Market in the US by Others: Incremental & Absolute Growth
Exhibit 66 OTC Drugs Market in US by Others 2020–2026 ($ billion)
Exhibit 67 OTC Drugs Market in the US: Vendors Market Shares 2020
Exhibit 68 Johnson & Johnson: Total Revenue 2018−2020 ($ billion)
Exhibit 69 Johnson & Johnson: Revenue by Business Segments 2018−2020 ($ billion)
Exhibit 70 Johnson & Johnson: R&D Expenditure 2018−2020 ($ billion)
Exhibit 71 Johnson & Johnson: Revenue Share by Geographic Regions 2018−2020 ($ billion)
Exhibit 72 GlaxoSmithKline: Total Revenue 2018−2020 ($ billion)
Exhibit 73 GlaxoSmithKline: Revenue by Business Segments 2018−2020 ($ billion)
Exhibit 74 GlaxoSmithKline: R&D Expenditure 2018−2020 ($ billion)
Exhibit 75 GlaxoSmithKline: Geographic Regions 2018−2020 ($ billion)
Exhibit 76 Bayer AG: Total Revenue 2018−2020 ($ billion)
Exhibit 77 Bayer AG: Revenue by Business Segments 2018−2020 ($ billion)
Exhibit 78 Bayer AG: R&D Expenditure 2018−2020 ($ billion)
Exhibit 79 Bayer AG: Revenue by Geographic Regions 2018−2020 ($ billion)
Exhibit 80 Teva Pharmaceutical Industries: Total Revenue 2018−2020 ($ billion)
Exhibit 81 Teva Pharmaceutical Industries: R&D Expenditure 2018−2020 ($ billion)
Exhibit 82 Teva Pharmaceutical Industries: Revenue by Geographic Regions 2018−2020 ($ billion)
List Of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2020
Table 3 Top Branded Drugs That Will Lose Their Patents By 2020
Table 4 OTC Drugs Launched by Companies as OTC 2010- 2015
Table 5 OTC Products to be Eligible for Reimbursement
Table 6 Latest Ingredients & Dosages transferred from Rx to OTC Status by FDA
Table 7 OTC Drugs Market in US by Product Type: Incremental and Absolute Growth
Table 8 OTC Drugs Market in the US: Ranking Vendors 2020
Table 9 Johnson & Johnson: Major Product Offerings
Table 10 GlaxoSmithKline: Major Product Offerings
Table 11 Bayer AG: Major Product Offerings
Table 12 Teva Pharmaceutical Industries: Major Product Offerings
Table 13 Abbott: Major Product Offerings
Table 14 Achelios: Major Product Offerings
Table 15 Alcon: Major Product Offerings
Table 16 American Health: Major Product Offerings
Table 17 Amway: Major Product Offerings
Table 18 Aytu Consumer Health: Major Product Offerings
Table 19 Bausch Health Companies: Major Product Offerings
Table 20 BioGaia: Major Product Offerings
Table 21 Colgate-Palmolive Company: Major Product Offerings
Table 22 Herbalife Nutrition: Major Product Offerings
Table 23 Perrigo Company: Major Product Offerings
Table 24 Prestige Consumer Health: Major Product Offerings
Table 25 Procter & Gamble: Major Product Offerings
Table 26 Reckitt Benckiser Group: Major Product Offerings
Table 27 sanofi-aventis: Major Product Offerings
Table 28 Sun Pharmaceutical Industries: Major Product Offerings
Table 29 The Bountiful Company: Major Product Offerings
Table 30 Viatris: Major Product Offerings
Table 31 OTC Drugs Market in US by Product Type 2020−2026 ($ billion)
Table 32 OTC Drugs Market in US by Product Type 2020−2026 (%)
Table 33 OTC Drugs Market in US by Indication 2020−2026 ($ billion)
Table 34 OTC Drugs Market in US by Indication 2020−2026 (%)
Table 35 OTC Drugs Market in US by Distribution Channel 2020−2026 ($ billion)
Table 36 OTC Drugs Market in = US by Distribution Channel 2020−2026 (%)
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Product Type
4.3.2 Market Segmentation by Indication
4.3.3 Market Segmentation by Distribution Channel
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at A Glance
7 Introduction
7.1 Overview
7.1.1 Launching OTC Drugs in US
7.1.2 Accessibility of OTC Drugs in US
7.1.3 Affordability of OTC Drugs in US
7.1.4 Optimizing OTC Drugs
7.1.5 Trends in Various OTC Therapeutic Categories
8 Market Opportunities & Trends
8.1 Private Labels & Online Sales of OTC Drugs
8.2 Patent Expirations of Prescription Drugs
8.3 OTC Product Launches & Replacement of Prescription Drugs
8.4 Impact of Healthcare Reforms on OTC Drugs
9 Market Growth Enablers
9.1 Growing Trend of Self Medication & Self Care
9.2 OTC Drugs Treating Serious Health Conditions
9.3 Switching of Prescription Drugs to OTC Drugs
9.4 Growing Healthcare Savings by OTC Drugs
10 Market Restraints
10.1 Abuse of OTC Drugs
10.2 Risk of Side Effects by OTC Counter Drugs
10.3 Growing Alternatives to OTC Drugs
11 Market Landscape
11.1 Market Overview
11.1.1 Product Insights
11.1.2 Indication Insights
11.1.3 Distribution Channel Insights
11.2 Market Size & Forecast
11.3 Impact of Covid-19 On the US OTC Drugs Market
11.4 Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Product Type
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Cold & Cough
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Analgesics
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.5 Dietary Supplements
12.5.1 Market Overview
12.5.2 Market Size & Forecast
12.6 Gastrointestinal
12.6.1 Market Overview
12.6.2 Market Size & Forecast
12.7 Dermatology
12.7.1 Market Overview
12.7.2 Market Size & Forecast
12.8 Ophthalmic
12.8.1 Market Overview
12.8.2 Market Size & Forecast
12.9 Others
12.9.1 Market Overview
12.9.2 Market Size & Forecast
13 Indication
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Infection
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Pain
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Heartburn
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Immune/Health Booster
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.7 Others
13.7.1 Market Overview
13.7.2 Market Size & Forecast
14 Distribution Channel
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Retail Pharmacies
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Hospital Pharmacies
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Online Pharmacies
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 Others
14.6.1 Market Overview
14.6.2 Market Size & Forecast
15 Competitive Landscape
15.1 Competition Overview
15.2 Market Share Analysis
15.2.1 Johnson & Johnson in OTC Drugs Market in US
15.2.2 GlaxoSmithKline in OTC Drugs Market in US
15.2.3 Bayer AG in OTC Drugs Market in the US
15.2.4 Teva Pharmaceutical Industries in OTC Drugs Market in the US
16 Key Company Profiles
16.1 Johnson & Johnson
16.1.1 Business Overview
16.1.2 Johnson & Johnson in OTC Drugs Market in US
16.1.3 Product Offerings
16.1.4 Key Strategies
16.1.5 Key Strengths
16.1.6 Key Opportunities
16.2 GlaxoSmithKline
16.2.1 Business Overview
16.2.2 GlaxoSmithKline in OTC Drugs Market in US
16.2.3 Product Offerings
16.2.4 Key Strategies
16.2.5 Key Strengths
16.2.6 Key Opportunities
16.3 Bayer AG
16.3.1 Business Overview
16.3.2 Bayer AG in OTC Drugs Market in the US
16.3.3 Product Offerings
16.3.4 Key Strategies
16.3.5 Key Strengths
16.3.6 Key Opportunities
16.4 Teva Pharmaceutical Industries
16.4.1 Business Overview
16.4.2 Teva Pharmaceutical Industries in OTC Drugs Market in US
16.4.3 Product Offerings
16.4.4 Key Strategies
16.4.5 Key Strengths
16.4.6 Key Opportunities
17 Other Prominent Vendors
17.1 Abbott
17.1.1 Business Overview
17.1.2 Product Offerings
17.2 Achelios
17.2.1 Business Overview
17.2.2 Product Offerings
17.3 Alcon
17.3.1 Business Overview
17.3.2 Product Offerings
17.4 American Health
17.4.1 Business Overview
17.4.2 Product Offerings
17.5 Amway
17.5.1 Business Overview
17.5.2 Product Offerings
17.6 Aytu Consumer Health
17.6.1 Business Overview
17.6.2 Product Offerings
17.7 Bausch Health Companies
17.7.1 Business Overview
17.7.2 Product Offerings
17.8 BioGaia
17.8.1 Business Overview
17.8.2 Product Offerings
17.9 Colgate-Palmolive Company
17.9.1 Business Overview
17.9.2 Product Offerings
17.10 Herbalife Nutrition
17.10.1 Business Overview
17.10.2 Product Offerings
17.11 Perrigo Company
17.11.1 Business Overview
17.11.2 Product Offerings
17.12 Prestige Consumer Health
17.12.1 Business Overview
17.12.2 Product Offerings
17.13 Procter & Gamble
17.13.1 Business Overview
17.13.2 Product Offerings
17.14 Reckitt Benckiser Group
17.14.1 Business Overview
17.14.2 Product Offerings
17.15 Sanofi-Aventis
17.15.1 Business Overview
17.15.2 Product Offerings
17.16 Sun Pharmaceutical Industries
17.16.1 Business Overview
17.16.2 Product Offerings
17.17 The Bountiful Company
17.17.1 Business Overview
17.17.2 Product Offerings
17.18 Viatris
17.18.1 Business Overview
17.18.2 Product Offerings
18 Report Summary
18.1 Key Takeaways
18.2 Strategic Recommendations
19 Quantitative Summary
19.1 Market by Product Type
19.2 Market by Indication
19.3 Market by Distribution Channel
20 Appendix
20.1 Abbreviations
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
What is the market size and forecast for the U.S. OTC drugs industry?
What are the different distribution channels for the OTC drugs?
Who are the key players in the on-the-counter drugs industry?
Which is the leading segment in the US OTC drugs market?
What is the impact of COVID-19 on the U.S. OTC drugs market?
other RELATED Reports
IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026
Published : February 2021
Personalized Nutrition Market - Global Outlook and Forecast 2021-2026
Published : June 2021